Caution with nalbuphine in patients on long-term opioids

Palliative Medicine

Volumn 19, Issue 2, 2005, Pages 168-

  Hartree, Colin ^a  

^a St Wilfrid's Hospice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; OXYCODONE;

ADULT; AGITATION; ANALGESIA; CANCER PAIN; CASE REPORT; DISEASE EXACERBATION; DRUG ANTAGONISM; HUMAN; LETTER; LONG TERM CARE; MALE; PELVIS PAIN SYNDROME; PROSTATE CARCINOMA; RECTUM CARCINOMA; RESTLESSNESS; SWEAT GLAND DISEASE; TACHYCARDIA; WITHDRAWAL SYNDROME;

ACUTE DISEASE; ANALGESICS, OPIOID; HUMANS; MALE; MIDDLE AGED; NALBUPHINE; NARCOTIC ANTAGONISTS; PAIN; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 15944378929     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/026921630501900218     Document Type: Article

References (6)

1. Dollery Sir C. Therapeutic drugs, second edition. Edinburgh: Churchill Livingstone, 1999.
2. Sweetman SC. Martindale. The complete drug reference, thirty-third edition. London: Pharmaceutical Press, 2002.
3. Preston KL, Bigelow GE, Liebson IA. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 1988; 248: 929–937.
4. Smith JE, Guly HR. Nalbuphine and slow release morphine. BMJ 2004; 328: 1426.
5. Twycross R, Wilcock A, Charlesworth S, Dickman A. Palliative care formulary, second edition. Oxford, UK: Radcliffe Medical Press, 2002.
6. British National Formulary, published by British Medical Association/Royal Pharmaceutical Society of GB 47; March 2004: 212.